CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $7.75B, above the global median of $1.18B
- PositionPrice-to-book is 75.22×, higher than 95% of its Biotechnology peers (median 5.43×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
7.75BUSDvs all stocks (USD)
Revenue (TTM)
239.92MUSDvs all stocks (USD)
Profit Margin
-85.59%vs Biotechnology peers
Beta
1.97xvs all stocks
52-Week Change
9.09%vs all stocks
Market Capitalization
7.75BUSDvs all stocks (USD)
Enterprise Value
7.64BUSDvs all stocks (USD)
Forward P/E
-184.04xvs Biotechnology peers
Price to Sales (TTM)
32.29xvs Biotechnology peers
Price to Book (MRQ)
75.22xvs Biotechnology peers
Enterprise to Revenue
31.85xvs Biotechnology peers
Enterprise to EBITDA
-38.29xvs Biotechnology peers
Gross Margin
87.47%vs Biotechnology peers
Profit Margin
-85.59%vs Biotechnology peers
Operating Margin
-68.14%vs Biotechnology peers
Return on Assets (TTM)
-30.96%vs Biotechnology peers
Return on Equity (TTM)
-117.05%vs Biotechnology peers
Revenue (TTM)
239.92MUSDvs all stocks (USD)
Revenue per Share (TTM)
3.56USDUpdated Aug 28, 2026Quarterly Revenue Growth
46.90%vs Biotechnology peers
Gross Profit (TTM)
213.53MUSDvs all stocks (USD)
EBITDA (TTM)
-199.55MUSDvs all stocks (USD)
Net Income (TTM)
-210.22MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
46.91%vs Biotechnology peers
Operating Cash Flow (TTM)
-105.35MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-130.59MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
189.76MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
19.49MUSDFY2025 · Dec 31, 2025Gross Profit
170.26MUSDFY2025 · Dec 31, 2025Operating Income
-192.02MUSDvs all stocks (USD)
Pre-tax Income
-196.04MUSDFY2025 · Dec 31, 2025Income Tax Expense
497.00KUSDFY2025 · Dec 31, 2025Net Income
-196.54MUSDFY2025 · Dec 31, 2025EBIT
-175.46MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-174.12MUSDFY2025 · Dec 31, 2025Research & Development
167.34MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
194.94MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
15.29MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
20.58MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.11USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.11USDFY2025 · Dec 31, 2025Basic Shares Outstanding
64.98MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
64.98MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-196.54MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-101.92MUSDFY2025 · Dec 31, 2025Free Cash Flow
-102.88MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
54.82MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-196.54MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.34MUSDFY2025 · Dec 31, 2025Stock-based Compensation
66.82MUSDFY2025 · Dec 31, 2025Other Non-cash Items
21.10MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-7.57MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
21.89MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-8.96MUSDFY2025 · Dec 31, 2025Capital Expenditures
-953.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-348.67MUSDFY2025 · Dec 31, 2025Sale of Investments
252.47MUSDFY2025 · Dec 31, 2025Other Investing Activity
-40.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-137.15MUSDFY2025 · Dec 31, 2025Other Financing Charges
-19.92MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
202.78MUSDFY2025 · Dec 31, 2025Shares Outstanding
68.82MSharesUpdated Aug 28, 2026Float Shares
56.03MSharesUpdated Aug 28, 2026Shares Short
10.15MSharesUpdated Aug 28, 2026Short Ratio
14.57daysvs all stocks
Short % of Shares Outstanding
14.86%vs all stocks
% Held by Insiders
0.71%vs all stocks
% Held by Institutions
114.67%vs all stocks
Total Cash (MRQ)
330.90MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.81USDUpdated Aug 28, 2026Total Debt (MRQ)
109.78MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.5052xvs Biotechnology peers
Current Ratio (MRQ)
3.45xvs Biotechnology peers
Book Value per Share (MRQ)
1.50USDUpdated Aug 28, 2026Total Assets
480.20MUSDvs all stocks (USD)
Total Current Assets
466.92MUSDFY2025 · Dec 31, 2025Total Liabilities
210.17MUSDFY2025 · Dec 31, 2025Total Non-current Assets
13.28MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
104.23MUSDFY2025 · Dec 31, 2025Total Current Liabilities
105.94MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
54.30MUSDFY2025 · Dec 31, 2025Other Short-term Investments
334.65MUSDFY2025 · Dec 31, 2025Accounts Receivable
26.08MUSDFY2025 · Dec 31, 2025Inventory
25.75MUSDFY2025 · Dec 31, 2025Accounts Payable
13.95MUSDFY2025 · Dec 31, 2025Short-term Debt
650.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
7.49MUSDFY2025 · Dec 31, 2025Other Current Liabilities
4.08MUSDFY2025 · Dec 31, 2025Long-term Debt
3.34MUSDFY2025 · Dec 31, 2025Common Stock (Book)
67.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.35BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
270.03MUSDvs all stocks (USD)
52-Week Low
74.50USDUpdated Aug 28, 202652-Week High
122.20USDUpdated Aug 28, 202652-Week Change
9.09%vs all stocks
Beta
1.97xvs all stocks
50-Day MA
109.21USDUpdated Aug 28, 2026200-Day MA
99.39USDUpdated Aug 28, 2026Avg 10-Day Volume
437.87KSharesUpdated Aug 28, 2026Avg 30-Day Volume
632.95KSharesUpdated Aug 28, 2026Diluted EPS (TTM)
-3.12USDUpdated Aug 28, 2026Other Income / Expense
1.26MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 75.22×, higher than 95% of its Biotechnology peers (median 5.43×)Significant
Price-to-book: 75.22Industry median: 5.43Industry P95: 38.26Peers compared: 194
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.87Profit Margin: -0.86
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 13.14
Consistent revenue growth patternNotable
Growth Consistency Score: 0.65
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $7.75B, above the global median of $1.18BNotable
Market cap (USD): 7,747,924,787Global Median: 1,179,398,897.704
Companies that share the same coordination system — how they create, deliver, or capture value.
InnoCare Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Allist Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ALK-Abello A/S
Tier 1ProductionApproval-Gated PipelineRule
Huadong Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Glenmark Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Spyre Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Demant A/S
Tier 1ProductionApproval-Gated PipelineFlowRule
Alkermes plc
Tier 1ProductionApproval-Gated PipelineRule
Grifols, S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Scholar Rock Holding Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Travere Therapeutics Inc.
2 interpretationsRevenue Growing With Receivables GrowingHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Urogen Pharma Ltd.
2 interpretationsRevenue Growing With Receivables GrowingHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Insmed Inc.
2 interpretationsRevenue Growing With Receivables GrowingHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC